---
title: "Xenetic Biosciences Q2 FY26 net loss widens 35% to $929,695; revenue rises 12% to $660,601"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295149650.md"
description: "Xenetic Biosciences reported a Q2 FY26 GAAP net loss of $929,695, widening 35% year-over-year, while revenue increased 12% to $660,601 due to higher Takeda sublicense royalties. Operating losses rose 34.1% to $971,690 as costs climbed 24.2%. R&D expenses fell 15.9%, but G&A surged 64.2% due to legal fees from a strategic review. The board is evaluating options like an asset sale or reverse merger while advancing its DNase program."
datetime: "2026-08-06T21:55:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295149650.md)
  - [en](https://longbridge.com/en/news/295149650.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295149650.md)
generator: "portal-rs"
---

# Xenetic Biosciences Q2 FY26 net loss widens 35% to $929,695; revenue rises 12% to $660,601

-   Xenetic Biosciences posted a GAAP net loss of USD 929,695 for the quarter ended June 30, 2026, widening 35% year over year. \* Revenue rose 12% to USD 660,601, driven by higher royalty revenue tied to its Takeda sublicense in certain countries. \* Operating loss widened 34.1% to USD 971,690 as total operating costs and expenses climbed 24.2% to USD 1.63 million. \* R&D expense fell 15.9% to USD 552,013, while G&A jumped 64.2% to USD 1.08 million on higher legal costs tied to a strategic review. \* The board is running a formal strategic review that includes options such as an asset sale or reverse merger, while continuing to advance its systemic DNase program. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenetic Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-006061), on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [XBIO.US](https://longbridge.com/en/quote/XBIO.US.md)
- [4502.JP](https://longbridge.com/en/quote/4502.JP.md)
- [TAK.US](https://longbridge.com/en/quote/TAK.US.md)

## Related News & Research

- [Takeda CHRO Nicola D. Greenway sells 12,980 ADS for $235,173.42](https://longbridge.com/en/news/296395853.md)
- [Takeda Pharmaceutical (NYSE:TAK) General Counsel Natalie Anne Marie Furney Sells 30,868 Shares of Stock](https://longbridge.com/en/news/295785108.md)
- [Xcel Energy sets BRL 0.26 per unit distribution for payment Oct. 26, 2026](https://longbridge.com/en/news/296646864.md)
- [Ecolab sets R$ 0.13 per unit distribution for Q3 2026, payable Oct. 21](https://longbridge.com/en/news/296635995.md)
- [Royalty Pharma EVP and Chairman of Partnering Christopher Hite sells 100,000 shares for $6 million](https://longbridge.com/en/news/296396564.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**